Qpex Biopharma Secures $33 Million Series A

Qpex Biopharma closed a $33 million Series A financing round and launched its infectious disease company. New Enterprise Associates led the financing syndicate featuring Adams Street Partners, LYZZ Capital, Hatteras Venture Partners, and Stanford University Draper Fund. Additional funding is being provided through an agreement with the Biomedical Advanced Research and Development Authority.

Qpex is focused on developing new antibiotics to combat the growing threat of global antimicrobial resistance. Upon closing the transaction, Qpex acquired the preclinical-stage anti-infective assets of The Medicines Company, including proprietary beta-lactamase inhibitor technology with unique pharmacological properties, including a broad spectrum of coverage.